Universal Health Services reported third-quarter 2026 adjusted EPS of $5.22, down 8% year over year, and adjusted EBITDA less noncontrolling interests of $625 million versus $671 million a year earlier. Results included $12 million of net favorable items—$47 million in supplemental Medicaid benefits offset by $26 million in additional liability reserves tied to a tentative Cumberland litigation settlement and $8.5 million in Talkspace transaction costs—that were not in July guidance. Stripping those out, CFO Steve Filton said adjusted EBITDA came in below internal expectations, driven by slower-than-expected ramp-ups at the Cedar Hill (D.C.) and Palm Beach Gardens (Fla.) de novo hospitals and a 0.7% decline in same-facility surgeries. Management reiterated full-year 2026 ranges but pointed to the lower end. The bigger focus was 2027: Filton estimated a $175 million-$200 million Medicaid supplemental payment headwind, plus $15 million from annualizing exchange declines, offset partially by recovering $80 million-$100 million of losses at Laurel Ridge and the two de novos. Talkspace synergies won't materialize until the back half of 2027.
UHS Misses Internal EBITDA Target as De Novo Ramp Sputters and Surgeries Slide, Flags $175M-$200M 2027 Medicaid Headwind
Universal Health Services closed its third quarter with adjusted EBITDA below its own internal expectations, as two flagship acute care de novo hospitals ramped more slowly than planned and surgical volumes decelerated more sharply than the company anticipated—a stumble that overshadowed broader demand strength and pushed management to the low end of its 2026 guidance range.
"Excluding these items, adjusted EBITDA less NCI was below our internal expectations despite modest sequential improvement," CFO Steve Filton told analysts on the call, referencing $12 million in net favorable items that were not in July guidance. "The shortfall primarily reflected a slower than expected ramp-up at our de novo hospitals and softer than expected surgical trends."
| Metric | Q3 2026 | Q3 2025 | Change |
|---|
| Adjusted EPS | $5.22 | — | -8% |
| Adjusted EBITDA less NCI | $625M | $671M | -6.9% |
| Net favorable items (not in July guide) | +$12M | — | — |
| Cash from operations | $637M | $381M | +67% |
| CapEx | $214M | — | — |
| Share repurchases | $242M (1.35M shares) | — | — |
| Total debt | $5.7B | — | — |
| Leverage | 2.17x | — | — |
| Cash | $169M | — | — |
The $12 million net favorable impact comprised $47 million of supplemental Medicaid benefits—which management had not contemplated in its July forecast—partially offset by $26 million of additional professional and general liability reserves, "primarily associated with the tentative settlement of a litigation matter related to our Cumberland facility in Virginia," Filton said, and $8.5 million of Talkspace transaction costs.
On a same-facility basis, acute care adjusted admissions rose 4.9% year over year, with emergency department visits up 4.6%—both characterized by management as broad-based geographically. But same-facility surgeries declined 0.7%, with inpatient and outpatient surgical cases falling at similar rates.
The divergence between medical and surgical volumes became the central analytical thread of the call. Inpatient medical admissions significantly outpaced surgical admissions, skewing pricing metrics: same-facility revenue per adjusted admission fell 1.7% on a reported basis. Filton estimated the medical-surgical mix shift accounted for roughly 100 basis points of drag, and that adjusting for exchange impacts, out-of-period Medicaid supplemental benefits, and the mix effect would put revenue per admission up approximately 3%—within the company's sustainable pricing range.
What is causing the surgical exodus? Filton attributed it to an acceleration of procedures moving to ambulatory surgery centers and physician offices, particularly in gastroenterology and orthopedics—not, he emphasized, to inpatient-only regulations. "I don't know that I have a great explanation for exactly why we, and I think the industry in general, has seen this acceleration in certain procedures to outpatient," he conceded under questioning from BofA's Kevin Fischbeck.
He described a compounding effect in gastroenterology: as more GI procedures migrate to outpatient settings, UHS has found it difficult to secure GI coverage for its emergency rooms. "Even our emergency room visits that are GI-related are being diverted to someplace else because we just don't have the coverage," Filton said.
The two acute care de novos, combined with the decertified Laurel Ridge Treatment Center in Texas, are expected to lose $80 million-$100 million in 2026—a figure that makes them simultaneously the year's biggest drag and potentially 2027's biggest tailwind.
Cedar Hill Regional Medical Center in Washington, D.C. opened in April 2025 with a busy emergency department, but surgical and procedural schedules have lagged because of a lack of physician infrastructure in Wards 7 and 8. "For years... there was really a lack of quality healthcare, and patients were leaving Ward 7 and 8 to get their healthcare elsewhere in the city," Filton said. "As a consequence, doctors really were not locating in Ward 7 and 8." UHS is now working with physician groups to establish practices in the area, but those practices remain at varying stages of development. The company pushed Cedar Hill's expected operational break-even to the first half of 2027, from prior expectations of the fourth quarter of 2026. The facility is losing roughly $10 million a month.
Palm Beach Gardens in Florida opened at the start of summer—not the company's original plan—after construction delays pushed the opening past the busy Florida season. It lost about $15 million in the quarter, though startup losses improved each month. "Structurally, I think everything we believed about the potential success of that hospital is still consistent with our original views, just taking a little bit longer to ramp up than we originally anticipated," Filton said.
| Behavioral Health Metric | Q3 2026 |
|---|
| Same-facility net revenue | +4.0% |
| Same-facility adjusted patient days | +2.1% |
| Same-facility revenue per adjusted patient day | +2.1% |
| Same-facility SWB per adjusted patient day | +3.6% |
| Headcount growth | ~1.5% |
Same-facility behavioral EBITDA was roughly flat despite the 4% revenue growth, a disconnect that Guggenheim's Jason Cassorla pressed management on. Filton acknowledged Laurel Ridge was "probably the single biggest drag." The facility, which earned $20 million-$25 million in pre-tax income annually before losing certification, is now losing $5 million-$10 million per quarter and is not expected to be recertified until 2027.
Wage inflation has moderated to roughly 3%-3.5% across both segments. Behavioral headcount growth decelerated to about 1.5%, which Filton said should now align with volume growth. In acute care, temporary and traveling labor rose just 3% in the most recent quarter—well controlled.
The company completed its acquisition of Talkspace on August 17; the contribution to third-quarter earnings was immaterial. CEO Marc Miller outlined three integration workstreams: deploying technology to smooth care transitions, establishing referral pathways between UHS facilities and Talkspace, and developing virtual intensive outpatient programs. "Those opportunities did not exist on either end previously. They exist now," Miller said. "We're just starting to see some of that come to fruition."
Filton said revenue synergies would begin materializing in the back half of 2027 and build over 12 to 24 months, with more detail to come in February.
The forward-looking conversation dominated the Q&A, with UBS's AJ Rice opening the questioning on 2027 puts and takes. Filton quantified what investors had been bracing for:
| 2027 Item | Estimated Impact |
|---|
| Medicaid supplemental payment reduction | $175M-$200M headwind |
| Exchange annualization (2H 2026 run rate) | $15M headwind |
| OB3 provider tax (Q4 2027 portion) | ~$10M included above |
| Loss-making facilities recovery (Laurel Ridge + 2 de novos) | $80M-$100M potential offset |
The Medicaid supplemental headwind primarily reflects prior-year amounts recorded in 2026 for DPP programs in Florida, Nevada, Ohio, California, and Washington, D.C. — benefits that will not repeat. Medicaid work requirements add another layer of uncertainty; Filton noted implementation could lag up to six months in certain states and that medical frailty exceptions remain a key open item. Medicaid represents approximately 15% of acute care adjusted admissions and 30% of behavioral patient days in expansion states.
The exchange headwind is built on annualizing the $50 million second-half 2026 run rate from an $85 million full-year negative impact. Exchange volumes fell 17% year over year, with a roughly one-for-one shift to self-pay. "Further changes in exchange enrollment could increase that number, and we'll have greater insight into that following the open enrollment period," Filton said.
Beyond the de novo ramp, analysts focused on three themes:
The health plan. The Medicare Advantage-focused plan, roughly 90% MA and 10% commercial, saw revenue growth of about 25% and is tracking to a ~$25 million tailwind in 2026. Filton said margins have moved from low negative single digits to low positive single digits and expects no material earnings impact up or down in 2027.
Capital allocation. Cash flow from operations of $637 million dwarfed the $381 million generated a year earlier. UHS repurchased 1.35 million shares for $242 million in the quarter, bringing year-to-date buybacks to $690 million, with $735 million remaining under authorization. CapEx is expected slightly below $1 billion for 2026 and to moderate toward $800 million beyond 2026 as large de novo projects conclude. Filton pushed back on characterizing that as maintenance-level: "I think that's a bit of an exaggeration. We sort of consider maybe 2% of our revenues to be devoted to maintenance capital. So something in that $250 million-$300 million range. So there's another $400 million, $500 million, $550 million of expansionary capital."
Growth algorithm credibility. Filton reaffirmed the long-term algorithms—acute care adjusted admission growth of 1.5%-2.5% (running about 2.6% for the year) and pricing of 2%-3% (running around 3%); behavioral patient day growth of 1%-2% (running about 1.7%) and pricing of 2%-3%. On the behavioral side, he acknowledged pricing is "towards the lower end of our range" after several years of robust increases, partly because the company is anniversarying prior DPP benefits and contractual increases from Managed Medicaid payers. Comparisons should ease next year.
UHS enters 2027 with a familiar healthcare-sector story: strong demand and disciplined labor costs, offset by regulatory pressure and capital projects that are taking longer to pay off. The $80 million-$100 million of losses at three facilities represents the clearest swing factor in either direction—recovery would provide a meaningful earnings cushion against the Medicaid supplemental roll-off, but the timing depends on regulatory recertification in Texas and physician recruitment in two underserved markets. Management will issue full 2027 guidance in February, when the market will learn whether the de novo maturation story is a timing issue or something more structural.